c
2
12
18
28
12
12
1a
14
e
12
16
a
a
2
2
a
20
32
1a
2a
19
Faculty
61 16
19
1
49
2
2
1a
32
34
1b
1d
18
35
5a
1d
2 29
1d
25
Kara N Maxwell, MD, PhD
78
5a
Assistant Professor of Medicine (Hematology-Oncology)
7
5f
Department: Medicine
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
3a
4
3
3
1d
3a
BRB Room 810
31 421 Curie Blvd
Philadelphia, PA 19104
26
31 421 Curie Blvd
Philadelphia, PA 19104
35
a7
12
18
Publications
23 a
3
2
4
b
1f
23 a
13
Education:
21 7 BS 23 (Genetics, Biochemistry) c
38 University of Wisconsin-Madison, 1998.
21 8 PhD 2b (Molecular and Cellular Biology) c
2f Rockefeller University, 2006.
21 7 MD 15 (Medicine) c
36 Weill Cornell Medical College, 2007.
c
3
27
21 7 BS 23 (Genetics, Biochemistry) c
38 University of Wisconsin-Madison, 1998.
21 8 PhD 2b (Molecular and Cellular Biology) c
2f Rockefeller University, 2006.
21 7 MD 15 (Medicine) c
36 Weill Cornell Medical College, 2007.
c
Links
c5 Search PubMed for articles
d
5
3
3
92
Permanent linkc5 Search PubMed for articles
d
2 29
21
1e
1d
24
5e
71
8
13 Maxwell Lab
2e https://www.med.upenn.edu/kmaxwelllab/
1c6 We are a translational human genetics and genomics research laboratory studying mechanisms of tumor formation in inherited cancer syndromes. We have a focus on breast and prostate cancer, but are interested in the broad range of tumor types affected by DNA repair deficiency. We are using multi-omics analyses of human samples coupled with in vitro and in vivo modelling systems to understand how tumors form in patients with inherited cancers.
8
1e0 For our work in prostate cancer genetics, we leverage the resources of the Basser Center for BRCA (https://www.basser.org/), the Penn Medicine Biobank (https://www.itmat.upenn.edu/biobank/), the Veterans' Affairs and Prostate Cancer Foundation Partnership (https://www.pcf.org/va-partnership/) and the VA Million Veterans' Program (https://www.mvp.va.gov/). Dr. Maxwell is the Director of the Basser Center’s Men and BRCA program (https://www.basser.org/brca/brca-men).
8
196 We are actively involved in many aspects of basic, translational and clinical research in Li Fraumeni Syndrome, caused by germline TP53 disease causing variants. We are one of the founding members of the EDISYN consortium (https://www.edisyn.org/) to study early cancer detection in patients with Li Fraumeni Syndrome, and we are active participants in the LIFTUp study (https://liftupstudy.org/).
8
17f We take a multi-disciplinary approach, collaborating with our colleagues across basic science labs and the clinical arena. Our research is funded by the National Cancer Institute, the Veterans’ Affairs Office of Research amd Development, the Prostate Cancer Foundation, the Burroughs Wellcome Foundation, the Li Fraumeni Syndrome Association and the Basser Center for BRCA.
8
57 Contact us for more details on rotation and post-doc projects in the fields of:
22 - Prostate cancer genetics
20 - BRCA1/2 cancers in men
39 - Li Fraumeni Syndrome and TP53-related disorders
31 - Mutational signatures in Veteran tumors
8
1c Lab Members 2024-25:
22 Greg Kelly MS, Lab Manager
2d Caitlin Orr PhD, Penn Project Manager
2c Leslie Grush AuD, VA Project Manager
30 KJ Johnson, Lab Administrative Assistant
28 Heena Desai MS, Bioinformatician
2a Ryan Hausler MS, Bioninformatician
35 Renyta Moses, CAMB Cancer Biology PhD Student
38 Taylor Crawford, CAMB Cancer Biology PhD Student
30 Nabamita Boruah PhD, Postdoctoral Fellow
22 Anh Le DO, Medicine Intern
33 Maliha Tayeb, Clinical Research Coordinator
34 Michael Wang, Clinical Research Coordinator
35 Rosella Delgado, Genetic Counseling Assistant
2c Sophia Spiegel, Penn Medical Student
2a Jillian O'Toole, Penn MS GC Student
e 29
27
Description of Clinical Expertise
82 cancer risk evaluation, breast cancer risk, hereditary breast ovarian cancer, Li Fraumeni Syndrome, Fanconi Anemia71
Description of Research Expertise
127 I am a Medical Oncologist with postdoctoral training in Cancer Genetics and PhD training in molecular and cellular biology. My research interests are in the genetics of human disease, particularly familial breast and prostate cancers, and in determinants of disease penetrance.8
13 Maxwell Lab
2e https://www.med.upenn.edu/kmaxwelllab/
1c6 We are a translational human genetics and genomics research laboratory studying mechanisms of tumor formation in inherited cancer syndromes. We have a focus on breast and prostate cancer, but are interested in the broad range of tumor types affected by DNA repair deficiency. We are using multi-omics analyses of human samples coupled with in vitro and in vivo modelling systems to understand how tumors form in patients with inherited cancers.
8
1e0 For our work in prostate cancer genetics, we leverage the resources of the Basser Center for BRCA (https://www.basser.org/), the Penn Medicine Biobank (https://www.itmat.upenn.edu/biobank/), the Veterans' Affairs and Prostate Cancer Foundation Partnership (https://www.pcf.org/va-partnership/) and the VA Million Veterans' Program (https://www.mvp.va.gov/). Dr. Maxwell is the Director of the Basser Center’s Men and BRCA program (https://www.basser.org/brca/brca-men).
8
196 We are actively involved in many aspects of basic, translational and clinical research in Li Fraumeni Syndrome, caused by germline TP53 disease causing variants. We are one of the founding members of the EDISYN consortium (https://www.edisyn.org/) to study early cancer detection in patients with Li Fraumeni Syndrome, and we are active participants in the LIFTUp study (https://liftupstudy.org/).
8
17f We take a multi-disciplinary approach, collaborating with our colleagues across basic science labs and the clinical arena. Our research is funded by the National Cancer Institute, the Veterans’ Affairs Office of Research amd Development, the Prostate Cancer Foundation, the Burroughs Wellcome Foundation, the Li Fraumeni Syndrome Association and the Basser Center for BRCA.
8
57 Contact us for more details on rotation and post-doc projects in the fields of:
22 - Prostate cancer genetics
20 - BRCA1/2 cancers in men
39 - Li Fraumeni Syndrome and TP53-related disorders
31 - Mutational signatures in Veteran tumors
8
1c Lab Members 2024-25:
22 Greg Kelly MS, Lab Manager
2d Caitlin Orr PhD, Penn Project Manager
2c Leslie Grush AuD, VA Project Manager
30 KJ Johnson, Lab Administrative Assistant
28 Heena Desai MS, Bioinformatician
2a Ryan Hausler MS, Bioninformatician
35 Renyta Moses, CAMB Cancer Biology PhD Student
38 Taylor Crawford, CAMB Cancer Biology PhD Student
30 Nabamita Boruah PhD, Postdoctoral Fellow
22 Anh Le DO, Medicine Intern
33 Maliha Tayeb, Clinical Research Coordinator
34 Michael Wang, Clinical Research Coordinator
35 Rosella Delgado, Genetic Counseling Assistant
2c Sophia Spiegel, Penn Medical Student
2a Jillian O'Toole, Penn MS GC Student
e 29
23
15d Raychaudhuri R, Garraway IP, Maxwell KN, Rettig M, Desai H, Schoen MW, Schweizer MT, Beltran H, Nelson PS, Montgomery B.: Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer. JCO Precis Oncol e2500341, Sep 2025 Notes: doi: 10.1200/PO-25-00341.
2b0 Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M: Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. Leukemia 39(9): 2087-2098. Sep 2025.
1cd Crawford TB, Nelson T, Karunamuni R, Desai H, Hausler R, Teerlink C, Carter H, Pagadala MS, Alba PR, DuVall SL, Danowski ME, Brunette CA, Ratner D, Garraway IP, Rose BS, Cooney KA, Vassy JL, Hauger RL, Lynch JA, Seibert TM, Maxwell KN: Association of HOXB13 G84E with prostate cancer among 592,158 men. J Natl Compr Canc Netw 23(10): e257055, Sep 2025 Notes: doi: 10.6004/jnccn.2025.7055.
185 Fischer NW, Ong N, Laverty B, Psarianos P, Giovino C, Alon N, Montellier E, Hainaut P, Maxwell KN, Kratz CP, Kafri R, Malkin D: TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup. Nat Commun 16(1): 8546, Sep 2025 Notes: doi: 10.1038/s41467-025-63528-6.
20a Crawford TB, Tayeb M, Barrett E, Al-Saleem T, Kondam P, Hausler R, Symecko H, Orr C, Wolfe C, Mann D, Spielman K, Wong G, Haas N, Narayan V, Robinson K, Takvorian S, Wong YN, Sokolova A, Montgomery RB, Menendez C, Kelley MJ, Aiello LB, Garraway IP, Domchek SM, Maxwell KN: Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients. medrxiv 2025.08.13.25333614, Aug 2025 Notes: doi: 10.1101/2025.08.13.25333614.
1b4 Green-Lott AY, Wadhwa A, Bailey AV, Kwan L, Haroldsen CL, Shelton JB, Lewis MS, Beenhouwer DO, Chamie K, Rose BS, Maxwell KN, Nickols NG, Yamoah K, Kelley MJ, Rebbeck TR, Schoen M, Rettig MB, Iyer HS, Garraway IP: Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration. Cancer 131(15): e70007, Aug 2025.
181 Cappadocia J, Maxwell KN, Nathanson KL, Bagley S, Powers J, Halper-Stromberg E, Roth JJ, Domchek S, Shah PD.: Exploration of possible association of BRIP1 pathogenic variants with central nervous system cancers in an institutional cohort. J Med Genet jmg-2025-11076, Aug 2025 Notes: DOI: 10.1136/jmg-2025-110764
145 Fernandes CJ, Du YK, Naumer A, Kagami LA, Le A, Good M, Duvall M, Powers J, Zelley K, Maese L, MacFarland S, Kohlmann W, Maxwell KN, Katona BW: Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome. Pancreas 54(7): e618-e623. Aug 2025.
1d7 Achatz MI, Villani A, Bertuch AA, Bougeard G, Chang VY, Doria AS, Gallinger B, Godley LA, Greer MC, Kamihara J, Khincha PP, Kohlmann WK, Kratz CP, MacFarland SP, Maese LD, Maxwell KN, Mitchell SG, Nakano Y, Pfister SM, Wasserman JD, Woodward ER, Garber JE, Malkin D.: Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res 31(10): 1831-1840, May 2025.
2c
7
1d
1f
Selected Publications
41d Johnatty SE, Tudini E, Parsons MT, Michailidou K, Zanti M, Canson D, Davidson AL, Berger T, Rosti RO, Kratz CP, Kalb R, McReynolds LJ, Giri N, Richardson M, Pesaran T, Surrallés J, Pujol R, Vundinti BR, George M, Maxwell KN, Nathanson K, Domchek S, Fiesco-Roa MÓ, Frias S, Garcia-de-Teresa B, Jongmans M, Lalani S, Maiburg M, Prescott K, Robinson R, Rajagopalan S, Blok LS, Temple SEL, Tucker K, Auerbach AD, Cancio MI, Kennedy JA, MacMillan ML, Tryon R, Wagner JE, Walsh M, Boddicker NJ, Hu C, Weitzel JN, Dingemans AJM, Hadler J, Rotenberg N, Ramadane-Morchadi L, de la Hoya M, James P, Van Overeem Hansen T, Vreeswijk MPG, Walker LC, Sharan SK, Easton DF, Couch F, Smogorzewska A, Nelson A, Ngeow J, Tischkowitz M, Gomez-Garcia E, Spurdle AB.: BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes. Am J Hum Genet S0002-9297(25): 00398-2, Oct 2025 Notes: DOI: 10.1016/j.ajhg.2025.10.007.15d Raychaudhuri R, Garraway IP, Maxwell KN, Rettig M, Desai H, Schoen MW, Schweizer MT, Beltran H, Nelson PS, Montgomery B.: Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer. JCO Precis Oncol e2500341, Sep 2025 Notes: doi: 10.1200/PO-25-00341.
2b0 Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M: Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. Leukemia 39(9): 2087-2098. Sep 2025.
1cd Crawford TB, Nelson T, Karunamuni R, Desai H, Hausler R, Teerlink C, Carter H, Pagadala MS, Alba PR, DuVall SL, Danowski ME, Brunette CA, Ratner D, Garraway IP, Rose BS, Cooney KA, Vassy JL, Hauger RL, Lynch JA, Seibert TM, Maxwell KN: Association of HOXB13 G84E with prostate cancer among 592,158 men. J Natl Compr Canc Netw 23(10): e257055, Sep 2025 Notes: doi: 10.6004/jnccn.2025.7055.
185 Fischer NW, Ong N, Laverty B, Psarianos P, Giovino C, Alon N, Montellier E, Hainaut P, Maxwell KN, Kratz CP, Kafri R, Malkin D: TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup. Nat Commun 16(1): 8546, Sep 2025 Notes: doi: 10.1038/s41467-025-63528-6.
20a Crawford TB, Tayeb M, Barrett E, Al-Saleem T, Kondam P, Hausler R, Symecko H, Orr C, Wolfe C, Mann D, Spielman K, Wong G, Haas N, Narayan V, Robinson K, Takvorian S, Wong YN, Sokolova A, Montgomery RB, Menendez C, Kelley MJ, Aiello LB, Garraway IP, Domchek SM, Maxwell KN: Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients. medrxiv 2025.08.13.25333614, Aug 2025 Notes: doi: 10.1101/2025.08.13.25333614.
1b4 Green-Lott AY, Wadhwa A, Bailey AV, Kwan L, Haroldsen CL, Shelton JB, Lewis MS, Beenhouwer DO, Chamie K, Rose BS, Maxwell KN, Nickols NG, Yamoah K, Kelley MJ, Rebbeck TR, Schoen M, Rettig MB, Iyer HS, Garraway IP: Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration. Cancer 131(15): e70007, Aug 2025.
181 Cappadocia J, Maxwell KN, Nathanson KL, Bagley S, Powers J, Halper-Stromberg E, Roth JJ, Domchek S, Shah PD.: Exploration of possible association of BRIP1 pathogenic variants with central nervous system cancers in an institutional cohort. J Med Genet jmg-2025-11076, Aug 2025 Notes: DOI: 10.1136/jmg-2025-110764
145 Fernandes CJ, Du YK, Naumer A, Kagami LA, Le A, Good M, Duvall M, Powers J, Zelley K, Maese L, MacFarland S, Kohlmann W, Maxwell KN, Katona BW: Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome. Pancreas 54(7): e618-e623. Aug 2025.
1d7 Achatz MI, Villani A, Bertuch AA, Bougeard G, Chang VY, Doria AS, Gallinger B, Godley LA, Greer MC, Kamihara J, Khincha PP, Kohlmann WK, Kratz CP, MacFarland SP, Maese LD, Maxwell KN, Mitchell SG, Nakano Y, Pfister SM, Wasserman JD, Woodward ER, Garber JE, Malkin D.: Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res 31(10): 1831-1840, May 2025.
2c
4d
22
22
7
10
a
a
2
2
19
18
10
22
10
11
c
5b © The Trustees of the University of Pennsylvania | Site best viewed a in a supported browser. | Site Design: 57 PMACS Web Team. 3 22
10